Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.9 Million SEK | 18.69% |
| 2022 | 12.55 Million SEK | 1.11% |
| 2021 | 12.41 Million SEK | -3.62% |
| 2020 | 12.88 Million SEK | 43.7% |
| 2019 | 8.96 Million SEK | 56.21% |
| 2018 | 5.73 Million SEK | 81.1% |
| 2017 | 3.16 Million SEK | 110.83% |
| 2016 | 1.5 Million SEK | 56.53% |
| 2015 | 960.43 Thousand SEK | 10.98% |
| 2014 | 865.42 Thousand SEK | 78.62% |
| 2013 | 484.5 Thousand SEK | 19.54% |
| 2012 | 405.31 Thousand SEK | 2.1% |
| 2011 | 396.96 Thousand SEK | -27.17% |
| 2010 | 545.04 Thousand SEK | -24.25% |
| 2009 | 719.56 Thousand SEK | 40.55% |
| 2008 | 511.95 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 FY | 14.9 Million SEK | 18.69% |
| 2023 Q4 | 14.9 Million SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 FY | 12.55 Million SEK | 1.11% |
| 2022 Q1 | - SEK | -100.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | 12.55 Million SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q4 | 12.41 Million SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 12.41 Million SEK | -3.62% |
| 2021 Q1 | - SEK | -100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 12.88 Million SEK | 43.7% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | 12.88 Million SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | 8.96 Million SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 FY | 8.96 Million SEK | 56.21% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q4 | 5.73 Million SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 5.73 Million SEK | 81.1% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 FY | 3.16 Million SEK | 110.83% |
| 2017 Q4 | 3.16 Million SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q4 | 1.5 Million SEK | 0.0% |
| 2016 FY | 1.5 Million SEK | 56.53% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | 960.43 Thousand SEK | 10.98% |
| 2015 Q4 | 960.43 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | 865.42 Thousand SEK | 0.0% |
| 2014 FY | 865.42 Thousand SEK | 78.62% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q4 | 484.5 Thousand SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 FY | 484.5 Thousand SEK | 19.54% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 FY | 405.31 Thousand SEK | 2.1% |
| 2012 Q2 | - SEK | -100.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | 405.31 Thousand SEK | 0.0% |
| 2012 Q1 | 309 Thousand SEK | -22.16% |
| 2011 Q1 | 440 Thousand SEK | -19.27% |
| 2011 Q4 | 396.96 Thousand SEK | -37.09% |
| 2011 FY | 396.96 Thousand SEK | -27.17% |
| 2011 Q3 | 631 Thousand SEK | -53.74% |
| 2011 Q2 | 1.36 Million SEK | 210.0% |
| 2010 Q2 | 773 Thousand SEK | 13.18% |
| 2010 Q4 | 545.04 Thousand SEK | -16.28% |
| 2010 Q3 | 651 Thousand SEK | -15.78% |
| 2010 Q1 | 683 Thousand SEK | -5.08% |
| 2010 FY | 545.04 Thousand SEK | -24.25% |
| 2009 Q4 | 719.56 Thousand SEK | 0.0% |
| 2009 Q1 | 507 Thousand SEK | 0.0% |
| 2009 FY | 719.56 Thousand SEK | 40.55% |
| 2008 FY | 511.95 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -745249900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 455.813% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 308.871% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Intervacc AB (publ) | 10.48 Million SEK | -42.183% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 596300.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 57.691% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -64.369% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 764458.974% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -373.175% |
| Saniona AB (publ) | 1.00 SEK | -1490499900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 1016.667% |
| Biovica International AB (publ) | 2.19 Million SEK | -577.808% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -1490499900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -616.587% |
| Xintela AB (publ) | 398 Thousand SEK | -3644.975% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -2029.286% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 1827.117% |
| Amniotics AB (publ) | 534 Thousand SEK | -2691.199% |
| 2cureX AB (publ) | -1000.00 SEK | 1490600.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 928.516% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 27.036% |
| Camurus AB (publ) | 100.95 Million SEK | 85.236% |
| Corline Biomedical AB | -3.85 Million SEK | 486.44% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -1490400.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | -248.248% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | -52.216% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 402.394% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -2633.674% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 65.956% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 3434.556% |
| Nanologica AB (publ) | 2.97 Million SEK | -401.345% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 4741.206% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | -25.844% |
| Alzinova AB (publ) | -3.27 Million SEK | 554.698% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -514.639% |
| Pila Pharma AB (publ) | 1.00 SEK | -1490499900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 1003128.264% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -269.484% |
| Simris Alg AB (publ) | 1.09 Million SEK | -1266.178% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 38.025% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 86.051% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -1349.903% |